arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Immunocore Holdings plc

IMCR
$28.44 ▼ -0.77 (-2.64%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
17 Visible periods
29 Metrics
Peer-ranked Benchmarks
Price Chart
30
Health
Poor
Bearish
auto_awesome

Analytical Summary

Immunocore Holdings plc faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $1.4B
Dividend Yield —
Revenue Growth 18.3% ↗
Op. Margin -2.6% ↘
ROIC -1.1% ↘
FCF / Share $0.30 ↗
Trailing P/E —
Price / Book 3.5x
FCF Yield 1.0%
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

17-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$115.93M
↑ +18.3% —
Net Income Profit after all expenses
$12.97M
↑ +158.2% —
Operating Margin Operating profit as % of sales
-2.6%
↓ -137.9% 14th
FCF / Share Free cash flow per share
$0.30
↑ +196.9% —
Long-Term Debt Long-term obligations
$438.69M
↓ -3.1% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability ↑
16
Returns ↑
35
Financial Health ↑
39
Cash Quality ↓
37

Dividend History

Dividend / share · sourced from SEC filings
$0.00 Latest / share

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 6 years · 17 quarters